| Literature DB >> 36235526 |
Aigerim Soltabayeva1, Nurbanu Dauletova1, Symbat Serik1, Margulan Sandybek1, John Okoth Omondi2, Assylay Kurmanbayeva3, Sudhakar Srivastava4.
Abstract
Plants live under different biotic and abiotic stress conditions, and, to cope with the adversity and severity, plants have well-developed resistance mechanisms. The mechanism starts with perception of the stimuli followed by molecular, biochemical, and physiological adaptive measures. The family of LRR-RLKs (leucine-rich repeat receptor-like kinases) is one such group that perceives biotic and abiotic stimuli and also plays important roles in different biological processes of development. This has been mostly studied in the model plant, Arabidopsis thaliana, and to some extent in other plants, such as Solanum lycopersicum, Nicotiana benthamiana, Brassica napus, Oryza sativa, Triticum aestivum, Hordeum vulgare, Brachypodium distachyon, Medicago truncatula, Gossypium barbadense, Phaseolus vulgaris, Solanum tuberosum, and Malus robusta. Most LRR-RLKs tend to form different combinations of LRR-RLKs-complexes (dimer, trimer, and tetramers), and some of them were observed as important receptors in immune responses, cell death, and plant development processes. However, less is known about the function(s) of LRR-RLKs in response to abiotic and biotic stresses. Here, we give recent updates about LRR-RLK receptors, specifically focusing on their involvement in biotic and abiotic stresses in the model plant, A. thaliana. Furthermore, the recent studies on LRR-RLKs that are homologous in other plants is also reviewed in relation to their role in triggering stress response processes against biotic and abiotic stimuli and/or in exploring their additional function(s). Furthermore, we present the interactions and combinations among LRR-RLK receptors that have been confirmed through experiments. Moreover, based on GENEINVESTIGATOR microarray database analysis, we predict some potential LRR-RLK genes involved in certain biotic and abiotic stresses whose function and mechanism may be explored.Entities:
Keywords: Arabidopsis; LRR-RLK receptors; abiotic stress; biotic stress; stress tolerance
Year: 2022 PMID: 36235526 PMCID: PMC9572924 DOI: 10.3390/plants11192660
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Number of LRR-RLKs present in different plants. Whole genome sequence data of the enlisted plant species was analyzed for the identification of LRR-RLKs. The identified LRR-RLK genes (numbers) with their expansion characteristic (presence of tandem duplication, motif conservation, and duplication) were based on different studies. Genome size for each species was given. Mb indicates mega base pairs. “-” indicates no data available.
| Numbers of | Plant Species | Genome Size | Presence of Tandem Duplication | LRR-RLK Organizations | References |
|---|---|---|---|---|---|
|
|
| 120 Mb | - | - | [ |
|
|
| 39.1 Mb | - | motif conservation | [ |
|
|
| 100 Mb | present | motif conservation | [ |
|
|
| 870 Mb | present | motif conservation | [ |
|
|
| 500 Mb | - | [ | |
|
|
| 658 Mb | present | - | [ |
|
|
| 367 Mb | present | segmental duplication | [ |
|
|
| 240 Mb | present | - | [ |
|
|
| 465 Mb | present | exon/intron organization, motif conservation | [ |
|
|
| 500 Mb | present | segmental duplication | [ |
|
|
| 133 Mb | present | - | [ |
|
|
| 320 Mb | present | - | [ |
|
|
| 1310 Mb | Present ( | motif conservation (both), segmental duplications ( | [ |
|
|
| 900 Mb | present | - | [ |
|
|
| 430 Mb | present | motif conservation | [ |
|
|
| 2400 Mb | present | random chromosomal distribution | [ |
|
|
| 280 Mb | present | - | [ |
|
|
| 840 Mb | present | lineage-specific expansion | [ |
|
|
| 265 Mb | present | - | [ |
|
|
| 574 Mb | present | motif conservation | [ |
|
|
| 1750 Mb | present | conserved exon/intron organization | [ |
|
|
| 370 Mb | present | - | [ |
|
|
| 455 Mb | present | intron/exon pattern organization, | [ |
|
|
| 515 Mb | present | motif conservation, segmental duplication | [ |
|
|
| 522 Mb | present | intra-chromosomal duplication, | [ |
|
|
| 430 Mb | present | exon duplication, mutation, and exon shuffling | [ |
|
|
| 939 Mb | present | - | [ |
|
|
| 761 Mb | present | motif conservation | [ |
|
|
| 512 Mb | present | exon/intron organization, motif conservation | [ |
|
|
| 500 Mb | present | segmental duplication, | [ |
|
|
| 920 Mb | present | segmental duplications, | [ |
|
|
| 750 Mb | present | - | [ |
|
|
| 1100–1150 Mb | present | exon/intron organizations, | [ |
|
|
| 17,000 Mb | present | segmental duplications, | [ |
|
|
| 2700 Mb | present | segmental duplication, | [ |
|
|
| 4780 Mb | present | segmental duplications | [ |
Figure 1Scheme of signaling pathways triggered by biotic- and abiotic-tested LRR-RLKs and crosstalk among them. The LRR-RLKs regulate various plant processes, including growth, development, and responses to biotic and abiotic stresses. After perceiving abiotic and/or biotic stimuli by the LRR-RLKs, activation of diverse signaling, such as MAPK activation (BAK1, PEPR1/2, SERK4), Ca2+ influx (BAK1), reactive oxygen species (ROS) production (RPK1, BAK1, RLK7, SOBIR1), BR signaling (BRI1, SERK2, SERK4), ABA signaling (KIN7, PXL2, RPK1, BRI1, SERK2, BAK1), jasmonate (JA), and salicylate (SA) (PEPR1/2, LRR1, PSKR1) occurs. Some LRR-RLKs may activate several signaling pathways depending on the type of stimuli: RPK1-ABA and ROS pathways; BRI and SERK2—ABA and BR pathway; PEPR1/2—MAPK and JA/SA pathway, SERK4—BR and MAPK pathway, BAK1-BR signaling, Ca2+ and MAPK pathways. Senescence may be associated with SARK and BIR1. Defense mechanisms against biotic stress stimuli are mediated by JA, SA, ROS, and MAPK pathways, and also additionally followed by LRR-RLKs: NIK1, EFR, RLP23, RLK902, NIK3, and FSL2. Yellow color indicates tested abiotic stimuli, blue color is for tested biotic stimuli, and green for both stimuli.
Experimentally proven and potential interactions of stress-related LRR-RLKs with LRR-RLK co-receptors from LRR II. Data taken from different well-studied research manuscripts and from ATTED database. The formation of heterodimers between the LRR-RLKs were labeled as “heterodimer” inside of box cross between two LRR-RLKs one from column and second from row. Below the heterodimer formation were shown the method/s of identifications heterodimer formation such as CoIP—coimmunoprecipitation; BiFC—bimolecular fluorescence complementation, gel filtration, pull-down, in vivo, genetically (by mutants analysis), kinase assay, co-sedimentation in solution, solid-phase assay. NA indicates not available data reported the formation of heterodimer/s. Grey colored box indicates that information taken from ATTED database about interaction was confirmed experimentally (published data), and white zone was not confirmed experimentally.
| LRR-RLK | SERK2 | SERK1 | SERK4/BKK1 | SERK3/BAK1 | SARK/Cik3 | NIK1 | NIK3/Cik1 | References |
|---|---|---|---|---|---|---|---|---|
|
| heterodimer (BiFC) | heterodimer (BiFC) | heterodimer (BiFC) | heterodimer (genetically, in vivo, pull-down) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
|
| heterodimer (in vivo) | heterodimer (in vivo) | heterodimer |
| heterodimer (in vitro, pull down) |
| [ |
|
| heterodimer (CoIP) | heterodimer (CoIP) | heterodimer (CoIP) | heterodimer (in vivo, CoIP) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
|
| heterodimer (genetically, in vivo) | heterodimer (in vivo) | heterodimer |
|
|
| [ |
|
|
| heterodimer (in vivo) | heterodimer | heterodimer | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
| heterodimer (genetically, CoIP) | heterodimer (genetically, CoIP) | heterodimer (solid-phase | heterodimer (genetically, pull-down, in vivo) | heterodimer (solid phase assay) | heterodimer (solid-phase assay) |
| [ |
|
| heterodimer (genetically, in vivo, in vitro) | heterodimer (genetically, in vivo, in vitro) |
| heterodimer (genetically, in vivo, in vitro) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) | [ |
|
| heterodimer (CoIP) | heterodimer |
| heterodimer | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
| heterodimer (genetically, CoIP) | heterodimer (BiFC, CoIP) | heterodimer (genetically) |
| heterodimer (solid-phase assay) | heterodimer | heterodimer (solid-phase assay) | [ |
|
| heterodimer (genetically, in vivo) | homodimer (genetically, in vivo) | heterodimer (solid-phase assay) | heterodimer (BiFC, CoIP) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
| homodimer (genetically, in vivo) | heterodimer (genetically, in vivo) |
|
|
|
| heterodimer (solid-phase assay) | [ |
|
| heterodimer (genetically, | heterodimer |
|
|
|
|
| [ |
|
| heterodimer (genetically, CoIP) | heterodimer (solid-phase assay) |
| heterodimer | Heterodimer (solid-phase assay) | Heterodimer (solid-phase assay) |
| [ |
|
|
| heterodimer (solid-phase assay) | heterodimer (solid-phase assay) | Heterodimer | Heterodimer |
|
| [ |
|
| heterodimer (solid-phase assay, co-sedimentation in solution) | heterodimer(molecular sieving) |
| heterodimer | heterodimer (solid-phase assay) |
|
| [ |
|
| heterodimer (solid-phase assay) |
|
| heterodimer (genetically, CoIP) |
|
|
| [ |
|
|
|
|
| heterodimer (genetically, pull-down, kinase assay) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
|
|
|
| heterodimer (pull-down, gel filtration) |
|
| heterodimer (solid-phase assay) | [ |
|
|
| heterodimer (solid-phase assay) | heterodimer (solid-phase assay) | heterodimer (genetically) | heterodimer (solid-phase assay) | heterodimer (solid-phase assay) |
| [ |
|
|
|
|
|
| heterodimer (in vivo, pull-down) | heterodimer (solid-phase assay) | heterodimer (genetically) | [ |
|
|
|
|
|
| heterodimer (in vivo, pull-down) |
| heterodimer (genetically) | [ |
|
| heterodimer (solid-phase assay) |
|
|
| heterodimer (pull-down) | heterodimer (solid-phase assay) | heterodimer (genetically, BiFC, CoIP) | [ |
|
|
|
|
|
| heterodimer (pull-down) | heterodimer (solid-phase assay) | heterodimer (genetically, BiFC, CoIP) | [ |